Pfizer Inc. (PFE) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Pharmaceuticals) last closed at $27.25. The rating moved from Neutral to Overbought on August 5, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$27.25
• Last changeMoved from Neutral to Overbought on August 5, 2026
• SectorHealthcare
• IndustryPharmaceuticals

See all overbought Healthcare stocks →

AI analysis

Pfizer benefits from a diversified revenue base, strong manufacturing scale and a pipeline that can capture upside from expanding interest in mRNA/biologics and oncology. Near-term technical and sentiment tailwinds could support modest multiple expansion while valuation appears constructive versus peers. However, ongoing payer optimization, pricing pressure, regulatory and competitive risks create meaningful execution risk. Expect steady cash generation and shareholder returns to underpin the name, with upside tied to positive clinical readouts or clearer demand recovery.

Key factors

• Large, diversified portfolio with stable cash flows and meaningful dividend/capital return capacity
• Pipeline and late-stage assets in oncology and biologics provide near- to mid-term upside and readthrough from positive mRNA/biologics data in the sector
• Attractive valuation relative to growth peers after recent market weakness, making upside more likely in risk-on environment
• Operational scale across R&D, manufacturing and global commercial footprint supports execution and market access
• Positive near-term technical and sentiment backdrop as risk-on flows rotate into growth/biotech names following dovish Fed commentary

Risks

• Pricing and reimbursement pressure tied to payer strategic rationalization and push for margin optimization
• Regulatory, litigation and policy risks (including potential White House actions affecting drug access/pricing)
• Competition in vaccines, biologics and small-molecule franchises leading to market-share erosion
• Pipeline clinical trial failures or disappointing readouts that could materially affect outlook
• Macroeconomic or geopolitical shocks that reverse risk-on flows and compress multiples
• Exposure to manufacturing or supply-chain disruptions for key products
• Limited near-term social-media momentum and absence of strong retail-driven catalysts in the immediate term

Latest MarketMoodz coverage

• U.S. Asking Prices Post Deepest Annual Drop Since 20172026-07-01
• ADP: June Private Payrolls 98K vs 118K Estimate — Job Growth Cools2026-07-01
• Innovent, Lilly Expand Verzenios Commercialization in China2026-07-01
• Trump: TSMC Arizona Expansion Could Push U.S. to 50% of Chips2026-07-01
• Pfizer's NSCLC ADC misses OS endpoint but shows signal in earlier-line patients2026-06-23

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.